ProteoStasis Therapeutics: $45 million first round, video interview with CEO
Here's the video... an interview with ProteoStasis CEO David Pendergast:
And here's the official press release, and some coverage of the company from BioWorld.
Labels: David Pendergast, Fidelity BioSciences, Genzyme, HealthCare Ventures, Novartis, proteomics, ProteoStasis Therapeutics, venture capital